continuing the journey to the marketplace | NVAX Message Board Posts


NVAX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  143444 of 147071  at  9/26/2021 1:55:57 PM  by

Marriott


continuing the journey to the marketplace

 In a " Morbidity and Mortality Weekly Report (MMWR) " issued by the Centers for Disease Control and Prevention , the following summary was declared :

-Two 2-dose mRNA COVID-19 vaccines (from Pfizer-BioNTech and Moderna) and a 1-dose viral vector vaccine (from Janssen [Johnson & Johnson]) are currently used in the United States.
 
-Among U.S. adults without immunocompromising conditions, vaccine effectiveness against COVID-19 hospitalization during March 11–August 15, 2021, was higher for the Moderna vaccine (93%) than the Pfizer-BioNTech vaccine (88%) and the Janssen vaccine (71%).

-Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.

for complete report :

www.cdc.gov/mmwr/volumes/70/wr/mm7038e1.htm

____________________________________

I look forward to a future report that declares :

-Among U.S. adults without immunocompromising conditions, vaccine effectiveness against COVID-19 hospitalization during ( a specified timeframe ) , was higher for the Novavax vaccine than the Moderna , Pfizer-BioNTech and the Janssen vaccine .



     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 3  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...